Navigation Links
VIVUS to Present at Four Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., Sept. 10 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that VIVUS management will present an overview of the company at four investment conferences during the month of September.  The conference presentation schedule is as follows:Bank of America Merrill Lynch Global Healthcare Conference Presented by: Timothy Morris, chief financial officerSeptember 16, 2010 at 2:30 p.m. BST Bank of America Merrill Lynch Financial Centre, London, UKStifel Nicolaus 2010 Healthcare ConferencePresented by: Dr. Wesley Day, vice president, clinical development September 17, 2010 at 9:45 a.m. EDTFour Seasons, Boston, MAUBS Global Life Sciences ConferencePresented by: Timothy Morris, chief financial officerSeptember 22, 2010 at 12:30 p.m. EDTThe Grand Hyatt, New York, NYThe Fifth Annual JMP Securities Healthcare ConferencePresented by: Timothy Morris, chief financial officerSeptember 28, 2010 at 8:30 a.m. EDTThe Palace Hotel, New York, NYA live audio webcast and 30-day archive of the presentations will be available at

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and an NDA has been filed and accepted by the FDA, with an action date of October 28, 2010. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. MUSE® (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit CONTACT:   VIVUS, Inc.Investor Relations:The Trout GroupTimothy E. MorrisBrian KorbChief Financial Officerbkorb@troutgroup.com650-934-5200646-378-2923Media Relations:GolinHarrisSusan Brophysbrophy@golinharris.com312-729-4359

Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. VIVUS to Present at Two Upcoming Investor Conferences
2. VIVUS Reports Third Quarter 2009 Highlights and Financial Results
3. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
4. VIVUS to Present at Four Upcoming Healthcare Conferences
5. VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
6. VIVUS to Present at the Needham and Company Life Sciences Conference
7. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
8. VIVUS Reports First Quarter 2009 Financial Results and Highlights
9. Paratek to Present Clinical Data at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy
10. Lexicon to Present at Stifel Nicolaus Healthcare Conference
11. WaferGen Corporate Presentation to be Webcast at Rodman and Renshaws 12th Annual Healthcare Conference
Post Your Comments:
(Date:11/27/2015)... , Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc (NYSE: ... today that it has closed the sale of its ... Guerbet (GBT- NYSE Euronext) in a transaction valued at ... manufacturing facilities and a total of approximately 1,000 employees ... St. Louis area. This entire ...
(Date:11/25/2015)... India , November 26, 2015 ... The Global Biobanking Market 2016 - 2020 report ... by maintaining integrity and quality in long-term samples, ... enabling long-term cost-effectiveness. Automation minimizes manual errors such ... the technical efficiency. Further, it plays a vital ...
(Date:11/25/2015)... Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... President and CEO of Neurocrine Biosciences, will be presenting ... New York . ... website approximately 5 minutes prior to the presentation to ... the presentation will be available on the website approximately ...
(Date:11/25/2015)... ... 25, 2015 , ... Jessica Richman and Zachary Apte, founders ... initial angel funding process. Now, they are paying it forward to other microbiome ... investments in the microbiome space. In this, they join other successful entrepreneurs-turned-angels ...
Breaking Biology Technology:
(Date:11/11/2015)...   MedNet Solutions , an innovative SaaS-based eClinical technology ... pleased to announce that it will be a Sponsor of ... to be held November 17-19 in Hamburg ... of iMedNet , MedNet,s easy-to-use, proven and ... has been able to deliver time and cost savings of ...
(Date:11/9/2015)... , Nov. 09, 2015 ... the addition of the "Global Law ... their offering. --> ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) has ...
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
Breaking Biology News(10 mins):